Advanced

Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction

Mohammad, Moman A. LU ; Andell, Pontus LU ; Koul, Sasha LU ; James, Stefan; Scherstén, Fredrik LU ; Götberg, Matthias LU and Erlinge, David LU (2017) In Platelets 28(4). p.414-416
Abstract

Patients pretreated with ticagrelor with less than 1 hour from percutaneous coronary intervention (PCI) or receiving ticagrelor in cath lab were prospectively included and received cangrelor. Cangrelor was infused for 2 hours and platelet function was assessed as P2Y12 reactivity units (PRU) with the VerifyNow P2Y12 function assay before start of infusion, 15 min after the start of infusion, and 30 min after the end of infusion. A total of n = 32 patients with an average age of 68 (±13) years with n = 22 (69%) males were included. The level of P2Y12 inhibition before cangrelor infusion was started was 249 PRU (IQR 221–271). After 15 min of cangrelor infusion the P2Y12 reactivity was markedly decreased to 71 PRU (IQR 52–104, p <... (More)

Patients pretreated with ticagrelor with less than 1 hour from percutaneous coronary intervention (PCI) or receiving ticagrelor in cath lab were prospectively included and received cangrelor. Cangrelor was infused for 2 hours and platelet function was assessed as P2Y12 reactivity units (PRU) with the VerifyNow P2Y12 function assay before start of infusion, 15 min after the start of infusion, and 30 min after the end of infusion. A total of n = 32 patients with an average age of 68 (±13) years with n = 22 (69%) males were included. The level of P2Y12 inhibition before cangrelor infusion was started was 249 PRU (IQR 221–271). After 15 min of cangrelor infusion the P2Y12 reactivity was markedly decreased to 71 PRU (IQR 52–104, p < 0.001). At 30 min after end of infusion PRU remained within the therapeutic range, 89 PRU (IQR 50–178; p < 0.001 for comparison with preinfusion) with only n = 4 (12.5%) patients with PRU >225. Results were consistent between patients receiving ticagrelor prehospital or in the cath lab and no statistical differences in PRU were noted between the two groups in any of the three measurements. In conclusion, cangrelor in combination with ticagrelor results in consistent and strong P2Y12 inhibition during and after infusion and cangrelor may bridge the gap until oral P2Y12 inhibitors achieve effect in real-world STEMI patients undergoing primary PCI.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cangrelor, myocardial infarction, PCI
in
Platelets
volume
28
issue
4
pages
414 - 416
publisher
Taylor & Francis
external identifiers
  • scopus:84997530304
  • wos:000405498700014
ISSN
0953-7104
DOI
10.1080/09537104.2016.1246714
language
English
LU publication?
yes
id
0fbf72b9-e1f6-4ee2-a5c7-aaab2d783061
date added to LUP
2016-12-09 12:38:55
date last changed
2018-01-07 11:40:09
@article{0fbf72b9-e1f6-4ee2-a5c7-aaab2d783061,
  abstract     = {<p>Patients pretreated with ticagrelor with less than 1 hour from percutaneous coronary intervention (PCI) or receiving ticagrelor in cath lab were prospectively included and received cangrelor. Cangrelor was infused for 2 hours and platelet function was assessed as P2Y12 reactivity units (PRU) with the VerifyNow P2Y12 function assay before start of infusion, 15 min after the start of infusion, and 30 min after the end of infusion. A total of n = 32 patients with an average age of 68 (±13) years with n = 22 (69%) males were included. The level of P2Y12 inhibition before cangrelor infusion was started was 249 PRU (IQR 221–271). After 15 min of cangrelor infusion the P2Y12 reactivity was markedly decreased to 71 PRU (IQR 52–104, p &lt; 0.001). At 30 min after end of infusion PRU remained within the therapeutic range, 89 PRU (IQR 50–178; p &lt; 0.001 for comparison with preinfusion) with only n = 4 (12.5%) patients with PRU &gt;225. Results were consistent between patients receiving ticagrelor prehospital or in the cath lab and no statistical differences in PRU were noted between the two groups in any of the three measurements. In conclusion, cangrelor in combination with ticagrelor results in consistent and strong P2Y12 inhibition during and after infusion and cangrelor may bridge the gap until oral P2Y12 inhibitors achieve effect in real-world STEMI patients undergoing primary PCI.</p>},
  author       = {Mohammad, Moman A. and Andell, Pontus and Koul, Sasha and James, Stefan and Scherstén, Fredrik and Götberg, Matthias and Erlinge, David},
  issn         = {0953-7104},
  keyword      = {Cangrelor,myocardial infarction,PCI},
  language     = {eng},
  number       = {4},
  pages        = {414--416},
  publisher    = {Taylor & Francis},
  series       = {Platelets},
  title        = {Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction},
  url          = {http://dx.doi.org/10.1080/09537104.2016.1246714},
  volume       = {28},
  year         = {2017},
}